The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Co-occurrence of ESR1 and PIK3CA mutations in HR+/HER2- metastatic breast cancer: Incidence and outcomes with targeted therapy.
 
Naomi Dempsey
Consulting or Advisory Role - Ashfield Healthcare; Curio Science; Gilead Sciences; MJH Life Sciences; Novartis; Precisca
Speakers' Bureau - Seagen
Travel, Accommodations, Expenses - Precisca
 
Priya Bhatt
Honoraria - OncLive/MJH Life Sciences; Total Health Conferencing
 
Courtney Lewis
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
Travel, Accommodations, Expenses - Guardant Health
 
Dana Tolman
Honoraria - Total Health Conferencing
Consulting or Advisory Role - Guardant Health AMEA
Speakers' Bureau - Pfizer
 
Yolcar Chamorro
No Relationships to Disclose
 
Muni Rubens
No Relationships to Disclose
 
Lauren Carcas
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca
 
Ana Cristina Sandoval-Leon
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Guardant Health; Merck; Oncocyte; Sanofi/Aventis; Sermonix Pharmaceuticals; Stemline Therapeutics
Research Funding - AstraZeneca (Inst); OBI Pharma (Inst); Seagen (Inst)
 
Manmeet Singh Ahluwalia
Stock and Other Ownership Interests - doctible; MedInnovate Advisors LLC; MimiVax; TriSalus Life Sciences
Honoraria - Elsevier; Peerview; Prime Education; Prime Oncology
Consulting or Advisory Role - AlloVir; Anheart Therapeutics; Apollomics; Autem Therapeutics; Bayer; Bugworks; Cairn Therapeutics; Caris Life Sciences; Equillium; GlaxoSmithKline; InSightec; Janssen; Menarini Group; Modifi Bio; NH TherAguix; Nuvation Bio; Prelude Therapeutics; Pyramid Biosciences; SDP Oncology; Siemens Healhineers/Varian Medical Systems; Sumitomo Dainippon Pharma Oncology; ViewRay; Voyager Therapeutics; Xoft
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst); Seagen (Inst)
Other Relationship - Idorsia (I); ResMed (I)
 
Reshma L. Mahtani
Consulting or Advisory Role - Agendia; Amgen; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech/Roche; Gilead Sciences; Hologic/Biotheranostics; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Sermonix Pharmaceuticals; Stemline Therapeutics
Speakers' Bureau - Seattle Genetics/Astellas
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Agendia; Amgen; AstraZeneca; bioTheranostics; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Seagen
 
Natasha Harpalani
No Relationships to Disclose